Early Stage Investigator (ESI) Grants

A key component of the ARLG Mentoring Program is the opportunity provided by Early Stage Investigator (ESI) Grants. The purpose of the ESI Grants is to allow trainees to generate preliminary data leading to additional external funding. ESI Grants can be used to support initial research in areas related to antibacterial resistance (AR) within the ARLG scope. In addition, funds that are part of the ESI Grants can be used to give ESIs access to isolates contained in the ARLG Virtual Biorepository Strain Catalogue.

There are three types of ESI Grants:

Early Faculty Seedling Award

The award provides 50% of current salary support per year for protected research for up to two years and up to $25,000 in direct costs for research over the two years. The applicant is required to provide confirmation for 25% of salary commitment from their institution of additional protected time for research above and beyond the 50% received as part of this award (Institutional Support Letter).

Individuals who are ID Fellows at the 4th or 5th year of fellowship, as well as MD or PhD (any discipline) with a faculty appointment of less than five years are eligible to apply. Applicants who work at a US domestic institution for the duration of the award irrespective of citizenship or visa status are eligible to apply. The clinical research project may be conducted in the US or internationally.

The program is currently full and we are not accepting applications for Early Faculty Seedling Award at this time. We anticipate re-opening in January 2025.

If you have questions about this opportunity, please contact us at ARLG_Network@dm.duke.edu.


ESI Seed Grants

Up to $50,000 in direct costs will be provided to ESI Seed Grant recipients for one year for research in areas related to AR within the ARLG scope. Individuals who are MD, PhD, or Pharm D students, graduate or post-graduate trainees, or those with a faculty appointment of less than five years are eligible to apply. Applicants who work at a US domestic institution for the duration of the award irrespective of citizenship or visa status are eligible to apply. The clinical research project may be conducted in the US or internationally.

The program is currently full and we are not accepting applications for  ESI Seed Grants at this time. We anticipate re-opening in January 2025.

If you have questions about this opportunity, please contact us at ARLG_Network@dm.duke.edu.

EVERYONE Grants

The ARLG has incorporated diversity, equity, and inclusion (DEI) as core values in recognition of DEI as key drivers of excellence and innovation in scientific research. As part of our mission, we are offering Early Stage Investigator Program Promoting Diversity in Antibiotic Resistance Research (EVERYONE) Grants.

Each year, up to $50,000 in direct costs will be provided via ARLG for up to two EVERYONE investigators for research in areas related to AR within the ARLG scope. EVERYONE investigators should be from underrepresented populations in the extramural scientific workforce as defined by the National Institutes of Health (NIH). Individuals who are MD, PhD, or Pharm D students, graduate or post-graduate trainees, or those with a faculty appointment of less than five years are eligible to apply. Applicants who work at a US domestic institution for the duration of the award irrespective of citizenship or visa status are eligible to apply. The clinical research project may be conducted in the US or internationally.

The goals of the EVERYONE Grants are to 1) foster diversity in the field of AR, 2) identify, develop, and support promising investigators in AR research, and 3) allow researchers to generate preliminary data leading to additional external funding.

The program is currently full and we are not accepting applications for  EVERYONE Grants at this time. We anticipate re-opening in January 2025.

If you have questions about this opportunity, please contact us at ARLG_Network@dm.duke.edu.

"Researchers from a range of diverse backgrounds are needed to help solve the complex problem of antibacterial resistance. We are really excited about the EVERYONE fellowship, which we hope will attract talented researchers into the field."

Melinda Pettigrew, PhD

Yale School of Public Health


“My primary mentor has been Vance Fowler, MD, and I have benefited tremendously from his leadership of the ARLG. I think this is the ultimate training ground for an early-career investigator with an interest in clinical trials that can address the crisis of antibacterial resistance.”

Thomas L. Holland, MD, MSc
Duke University

 

Apply Now

For additional ESI Grant information, please refer to: ARLG ESI GRANTS AT A GLANCE.